Orchard G E
Histopathology Department, St. John's Dermatology Centre, St. Thomas' Hospital, London, UK.
Histochem J. 2000 Aug;32(8):475-81. doi: 10.1023/a:1004192232357.
A panel of three melanocyte differentiation antibodies has been compared with anti-S100 protein and NKIC3 in an assessment of benign and malignant melanocytic lesions. Anti-polyclonal S100 protein labelled all cases of primary cutaneous malignant melanoma, metastatic melanoma, desmoplastic melanoma and myxoid melanomas. In addition all benign and dysplastic naevi were positive. Conversely, HMB 45 was the least sensitive marker, labelling 24/31 primary cutaneous melanomas, 14/24 metastatic melanomas and only 1/6 desmoplastic melanomas. In the case of naevi, only junctional forms labelled consistently. Results for anti-melan-A and anti-tyrosinase were similar, although anti-tyrosinase proved slightly more sensitive in cases of malignant melanoma. NKIC3 revealed similar results to anti-tyrosinase, but had the disadvantage of reduced selectivity. It is concluded that anti-tyrosinase and anti-melan-A are useful additions to the panel of melanocytic monoclonal antibodies. In addition, both antibodies appear to have greater sensitivity for malignant melanoma than the conventionally used HMB 45 and could be considered as supportive markers to polyclonal anti-S100 protein in the diagnosis of malignant melanoma.
在对良性和恶性黑素细胞性病变的评估中，将一组三种黑素细胞分化抗体与抗S100蛋白和NKIC3进行了比较。抗多克隆S100蛋白标记了所有原发性皮肤恶性黑色素瘤、转移性黑色素瘤、促纤维增生性黑色素瘤和黏液样黑色素瘤病例。此外，所有良性和发育异常痣均呈阳性。相反，HMB 45是最不敏感的标志物，标记了24/31例原发性皮肤黑色素瘤、14/24例转移性黑色素瘤，仅1/6例促纤维增生性黑色素瘤。在痣的情况下，只有交界型始终标记阳性。抗黑素A和抗酪氨酸酶的结果相似，尽管在恶性黑色素瘤病例中抗酪氨酸酶的敏感性略高。NKIC3显示出与抗酪氨酸酶相似的结果，但缺点是选择性降低。结论是，抗酪氨酸酶和抗黑素A是黑素细胞单克隆抗体组中有价值的补充。此外，这两种抗体对恶性黑色素瘤的敏感性似乎都高于传统使用的HMB 45，在恶性黑色素瘤的诊断中可被视为多克隆抗S100蛋白的辅助标志物。
